Sonneveld P, Moreau P, Einsele H, Quach H, Ho P, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, Perrot A, Cavo M, Belotti A, Broijl A, Pei H, Sitthi-Amorn A, Carson R, Rodríguez-Otero P, Dimopoulos M, Boccadoro M. P12 | SUBCUTANEOUS DARATUMUMAB (DARA) + BORTEZOMIB/LENALIDOMIDE/DEXAMETHASONE WITH DARA + LENALIDOMIDE MAINTENANCE IN TRANSPLANT-ELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: ANALYSIS OF SUSTAINED MINIMAL RESIDUAL DISEASE NEGATIVE. Haematologica 2026; 111(s2); https://doi.org/10.3324/haematol.2026.s2.14037.